维普中文期刊产品整合服务
31篇 您的检索式:作者名="Friemann"
    题名 作者 年代 出处 被引量
1Mammalian heparanase: gene cloning, expression and function in tumor progression and metastasis 显示文摘Vlodavsky I Friemann Y Elkin M 1999Nat Med1999,5,7:1
2Mammalian heparanase : gene- cloning, expression and function in tumor progression and metastasis 显示文摘Vlodavsky I Friemann Y Elkin M 1999Nat Med1999,5,7:1
3Nimotuzumab, an antitumor antibody that targets the epidermal growth factor receptor, blocks ligand binding while permitting the active receptor conformation 显示文摘Talavera A Friemann R G6mez-Puerta S 2009Cancer Res2009,69,14:1
4Sequence of acDNA encoding nitrite reductase from the treeBetula pendula and identification of conservedprotein regions显示文摘Friemann A Brinkmann K Hachtel W 1992Molecular and General GeneticsMGG1992,231,3:1
5Nimotuzumab an antitumor antibody that targets the epider- mal growth factor receptor blocks lig and binding while permitting the active receptor conformation 显示文摘TalALaver A Friemann R Gomez Puerta S 2009Cancer Res2009,69,14:1
6Nimo- tuzumab ,an antitumor antiboby that targets the epidermal growth factor receptor, blocks ligand binding while permit- ting the active receptor conformation显示文摘Talavera A Friemann R G6mez-Puerta S 2009Cancer Res2009,69,14:1
7Mammalian heparanase : gene cloning, expression and function in tumor progression and metastasis 显示文摘Vlodavsky I Friemann Y Elikin M 1999Nat Med1999,5,7:1
8Crystal structure of plant pectin methylesterase 显示文摘Johansson K EI-Ahmad M Friemann R JOrnvaH H Markovifi O Eklund H 2002FEBS Letters2002,514,2:1
9Improvement of nephrotoxicity,hypertension,and lipid metabolism after conversion of kidney transplant recipient from cyclosporin to tacrolimus显示文摘Friemann S Feuring E Padberg W 1998Transplant Proc1998,30,:1
10Mammalian heparanase:gene cloning,expression and function in tumor progression and metastasis 显示文摘Vlodavsky I Friemann Y Elkin M 1999Nat Med1999,5,7:1
11Nimo- tuzumab an antitumor antibody that targets the epidermal growth factor receptor blocks lig and binding while permit- ring the active receptor conformation显示文摘Talavera A Friemann R Gomez Puerta S 2009Cancer Res2009,69,14:1
12Nimotuzum- ab,on antitumor antibody that tesrgets the epidermal growth factor receptor, blocks ligand binding while permitting the ac- tive receptor conformation 显示文摘Talavera A Friemann R Gomez Puerta S et a l 2009Cancer Res2009,69,14:1
13Mammalian heparanase:gene cloning expression and function in tumor progression and metastasis显示文摘Vlodavsky I Friemann Y Elkin M 2006Nat Med2006,5,7:1
14Nimo- tuzumab, an antitumor antibody that targets the epidermal growth factor receptor, blocks lig and binding while permitting the active receptor conformation显示文摘TALAVERA A FRIEMANN R GOMEZ PUERTA S 2009Cancer Res2009,69,14:1
15Nimotuzumab,an antitumor antibody that targets the epidermal growth factor receptor,blocks ligand binding while permitting the active receptor conformation显示文摘Talavera A Friemann R G ó mez-Puerta S 0,,14:1
16Nimotuzumab, all an-titumor antibody that targets the epiderm al growth factor receptor,blocks lig and binding while perm itting the active receptorb confor-mation 显示文摘Talaera A Friemann R Gomeapuerta S 2009Cancer Res2009,69,14:1
17Nimotuzumab,an antitumor antibody that targets the epidermal growth factor receptor,blocks lig and binding while permitting the active receptor conformation显示文摘TALAVERA A FRIEMANN R GOMEZ PUERTA S 2009Cancer Res2009,69,14:1
18comersion to tacrolimus in hypenlipidemic patients 显示文摘Friemanns Stoppk Christ B 1999Transplant Proe1999,,:1
19Improvement of nephrotoxicity,hypertension,and lipid metabolism after conversion of kidney transplant recipients from cyclosporine to tacrolimus显示文摘Friemann S Feuring E Padberg W 1998Transplant Proc1998,30,:1
20Nimotuzumab,an antitumor antibody that targets the epidermal growth factor recep-tor,blocks lig and binding while permitting the active receptor con-formation显示文摘Talavera A Friemann R Gomez-Puerta S 0,,14:1
返回顶部 每页显示:
共2页 首页 上一页 第1页 下一页 末页 /2 跳转

网站首页 | 关于我们 | 联系我们 | 产品服务 | 客服中心 | 广告服务 | 版权声明 | 网站联盟 | 友情链接 | 售卡网点

版权所有© 渝B2-20050021-1 渝公网安备 50019002500403号 违法和不良信息举报中心

互联网出版许可证 新出网证(渝)字10号 全国400电话 - 免长途话费